On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Submits Application for Research License to Health Canada

  • Lexaria has developed its DehydraTECH technology
  • The company also has four new subsidiaries
  • Lexaria recently submitted its application to Health Canada for a research license

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses its DehydraTECH technology – a drug delivery platform. It is the only company globally with a patent issued for oral delivery of all cannabinoids. The company’s technology facilitates the delivery of bioactive substances via oral ingestion without the need for inhalational dosing or co-administration with sugars or sweeteners. Lexaria Bioscience is headquartered in Kelowna, British Columbia.

Lexaria has four new wholly owned subsidiary companies (http://nnw.fm/ANH5c). The four subsidiaries are Lexaria CanPharm Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp. and Lexaria Pharmaceutical Corp. Each of the subsidiaries are bestowed with the company’s patented DehydraTECH drug delivery platform.

The DehydraTECH drug delivery platform promotes healthier ingestion methods. It significantly improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other valuable molecules. DehydraTECH increases bioabsorption five to 10 times and reduces time of onset (http://nnw.fm/L6pWZ). This drug delivery platform is patented for cannabidiol and all other non-psychoactive cannabinoids (http://nnw.fm/hyR36).

The DehydraTECH drug delivery technology may potentially apply to the treatment of nervous system diseases, including Alzheimer’s. Lexaria (while not partnering with the tobacco industry) is gauging the potential use of the technology for nicotine delivery. DehydraTECH has been shown to deliver nicotine to the brain faster than customary delivery systems.

Recently, Lexaria Bioscience submitted its application to Health Canada for a research license. In addition, the company appointed a chief legal officer. Lexaria submitted its research application under Health Canada’s Cannabis Tracking and Licensing System for the operation of a research and development (R&D) laboratory to work with cannabinoids within the company’s new Kelowna head office, now under construction. In fact, Lexaria will commence experimental work on nicotine formulations, NSAIDs, vitamins and other bioactive compounds of interest after the completion of this laboratory facility.

The construction of the new head office and laboratory is advancing fast. Lexaria expects to occupy the new facility by the end of January 2019. The company is recruiting more staff to prepare for more wide-ranging operations. Moreover, Lexaria has taken delivery of specific equipment in a separate location where it is uniting known nano-emulsification processes with its DehydraTECH drug delivery platform for enhanced performance characteristics. This work will also transition to the Kelowna laboratory upon the facility being operational and licensed.

Furthermore, Lexaria appointed Dr. Ed Ergenzinger as its above-mentioned chief legal officer. Ergenzinger was also appointed senior vice president of innovation for Lexaria. He is a U.S. licensed patent attorney, holds a doctorate in neuroscience and is an adjunct professor of law. Ergenzinger is lead author or co-author on more than 40 scientific and legal publications.

Lexaria Bioscience continues to progress in its initiatives regarding its new laboratory in Kelowna and its advancements in innovation via the DehydraTECH drug delivery platform. In essence, the company’s focus is technology for the improved delivery of bioactive compounds. With this focus, Lexaria offers significant opportunity to those interested in this new paradigm in drug delivery technology.

For more information, visit the company’s website at www.LexariaBioscience.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217